Inflammatory myofibroblastic tumour - Revision history

Michael: /* IHC */

2024-03-26T00:28:04Z

IHC

← Older revision		Revision as of 00:28, 26 March 2024
Line 83:		Line 83:
	*CD117 -ve.		*CD117 -ve.
	**Case report of CD117 +ve.<ref name=pmid24938355/>		**Case report of CD117 +ve.<ref name=pmid24938355/>
			*CD30 -ve.

	Variable staining with:		Variable staining with:

Michael: /* General */

2019-03-18T00:01:08Z

General

← Older revision		Revision as of 00:01, 18 March 2019
Line 40:		Line 40:
	May be treated with:		May be treated with:
	*[[ALK inhibitors]].<ref name=pmid30790150>{{Cite journal \| last1 = Honda \| first1 = K. \| last2 = Kadowaki \| first2 = S. \| last3 = Kato \| first3 = K. \| last4 = Hanai \| first4 = N. \| last5 = Hasegawa \| first5 = Y. \| last6 = Yatabe \| first6 = Y. \| last7 = Muro \| first7 = K. \| title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. \| journal = Invest New Drugs \| volume = \| issue = \| pages = \| month = Feb \| year = 2019 \| doi = 10.1007/s10637-019-00742-2 \| PMID = 30790150 }}</ref>		*[[ALK inhibitors]].<ref name=pmid30790150>{{Cite journal \| last1 = Honda \| first1 = K. \| last2 = Kadowaki \| first2 = S. \| last3 = Kato \| first3 = K. \| last4 = Hanai \| first4 = N. \| last5 = Hasegawa \| first5 = Y. \| last6 = Yatabe \| first6 = Y. \| last7 = Muro \| first7 = K. \| title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. \| journal = Invest New Drugs \| volume = \| issue = \| pages = \| month = Feb \| year = 2019 \| doi = 10.1007/s10637-019-00742-2 \| PMID = 30790150 }}</ref>
	*[[~~Crizotinib~~]].<ref name=pmid30642440>{{Cite journal \| last1 = Mai \| first1 = S. \| last2 = Xiong \| first2 = G. \| last3 = Diao \| first3 = D. \| last4 = Wang \| first4 = W. \| last5 = Zhou \| first5 = Y. \| last6 = Cai \| first6 = R. \| title = Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. \| journal = Lung Cancer \| volume = 128 \| issue = \| pages = 101-104 \| month = Feb \| year = 2019 \| doi = 10.1016/j.lungcan.2018.12.016 \| PMID = 30642440 }}</ref>		*Drugs that act on ROS1 rearrangements, e.g. [[crizotinib]].<ref name=pmid30642440>{{Cite journal \| last1 = Mai \| first1 = S. \| last2 = Xiong \| first2 = G. \| last3 = Diao \| first3 = D. \| last4 = Wang \| first4 = W. \| last5 = Zhou \| first5 = Y. \| last6 = Cai \| first6 = R. \| title = Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. \| journal = Lung Cancer \| volume = 128 \| issue = \| pages = 101-104 \| month = Feb \| year = 2019 \| doi = 10.1016/j.lungcan.2018.12.016 \| PMID = 30642440 }}</ref>

	==Gross==		==Gross==

Michael: /* General */

2019-03-17T23:51:32Z

General

← Older revision		Revision as of 23:51, 17 March 2019
Line 37:		Line 37:
	*Mostly benign.		*Mostly benign.
	*Children & young adults.		*Children & young adults.

			May be treated with:
			*[[ALK inhibitors]].<ref name=pmid30790150>{{Cite journal \| last1 = Honda \| first1 = K. \| last2 = Kadowaki \| first2 = S. \| last3 = Kato \| first3 = K. \| last4 = Hanai \| first4 = N. \| last5 = Hasegawa \| first5 = Y. \| last6 = Yatabe \| first6 = Y. \| last7 = Muro \| first7 = K. \| title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. \| journal = Invest New Drugs \| volume = \| issue = \| pages = \| month = Feb \| year = 2019 \| doi = 10.1007/s10637-019-00742-2 \| PMID = 30790150 }}</ref>
			*[[Crizotinib]].<ref name=pmid30642440>{{Cite journal \| last1 = Mai \| first1 = S. \| last2 = Xiong \| first2 = G. \| last3 = Diao \| first3 = D. \| last4 = Wang \| first4 = W. \| last5 = Zhou \| first5 = Y. \| last6 = Cai \| first6 = R. \| title = Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. \| journal = Lung Cancer \| volume = 128 \| issue = \| pages = 101-104 \| month = Feb \| year = 2019 \| doi = 10.1016/j.lungcan.2018.12.016 \| PMID = 30642440 }}</ref>

	==Gross==		==Gross==

Michael: /* Molecular */

2019-03-17T23:48:02Z

Molecular

← Older revision		Revision as of 23:48, 17 March 2019
Line 88:		Line 88:
	==Molecular==		==Molecular==
	*ALK rearrangements.<ref name=pmid21297584/>		*ALK rearrangements.<ref name=pmid21297584/>
			*ROS1 rearrangements.<ref name=pmid30642440>{{Cite journal \| last1 = Mai \| first1 = S. \| last2 = Xiong \| first2 = G. \| last3 = Diao \| first3 = D. \| last4 = Wang \| first4 = W. \| last5 = Zhou \| first5 = Y. \| last6 = Cai \| first6 = R. \| title = Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. \| journal = Lung Cancer \| volume = 128 \| issue = \| pages = 101-104 \| month = Feb \| year = 2019 \| doi = 10.1016/j.lungcan.2018.12.016 \| PMID = 30642440 }}</ref>

	==See also==		==See also==

Michael at 03:09, 8 March 2017

2017-03-08T03:09:34Z

← Older revision		Revision as of 03:09, 8 March 2017
Line 7:		Line 7:
	\| Micro = inflammation ([[plasma cells]] - predominant, lymphocytes, eosinophils), [[spindle cells]] without atypia +/-fascicular architecture, +/-mitoses (none atypical), +/-[[necrosis]], +/-hemorrhage, +/-calcification		\| Micro = inflammation ([[plasma cells]] - predominant, lymphocytes, eosinophils), [[spindle cells]] without atypia +/-fascicular architecture, +/-mitoses (none atypical), +/-[[necrosis]], +/-hemorrhage, +/-calcification
	\| Subtypes =		\| Subtypes =
	\| LMDDx = [[calcifying fibrous pseudotumour]], [[inflammatory fibroid tumour]], [[nodular fasciitis]], [[gastrointestinal stromal tumour]]		\| LMDDx = [[calcifying fibrous pseudotumour]], [[inflammatory fibroid tumour]], [[nodular fasciitis]], [[gastrointestinal stromal tumour]], [[epithelioid inflammatory myofibroblastic sarcoma]]
	\| Stains =		\| Stains =
	\| IHC =		\| IHC =

Michael: /* Microscopic */

2017-03-08T03:09:16Z

Microscopic

← Older revision		Revision as of 03:09, 8 March 2017
Line 61:		Line 61:
	*[[Gastrointestinal stromal tumour]].<ref name=pmid24938355>{{Cite journal \| last1 = Kataoka \| first1 = TR. \| last2 = Yamashita \| first2 = N. \| last3 = Furuhata \| first3 = A. \| last4 = Hirata \| first4 = M. \| last5 = Ishida \| first5 = T. \| last6 = Nakamura \| first6 = I. \| last7 = Hirota \| first7 = S. \| last8 = Haga \| first8 = H. \| last9 = Katsuyama \| first9 = E. \| title = An inflammatory myofibroblastic tumor exhibiting immunoreactivity to KIT: a case report focusing on a diagnostic pitfall. \| journal = World J Surg Oncol \| volume = 12 \| issue = \| pages = 186 \| month = \| year = 2014 \| doi = 10.1186/1477-7819-12-186 \| PMID = 24938355 }}</ref>		*[[Gastrointestinal stromal tumour]].<ref name=pmid24938355>{{Cite journal \| last1 = Kataoka \| first1 = TR. \| last2 = Yamashita \| first2 = N. \| last3 = Furuhata \| first3 = A. \| last4 = Hirata \| first4 = M. \| last5 = Ishida \| first5 = T. \| last6 = Nakamura \| first6 = I. \| last7 = Hirota \| first7 = S. \| last8 = Haga \| first8 = H. \| last9 = Katsuyama \| first9 = E. \| title = An inflammatory myofibroblastic tumor exhibiting immunoreactivity to KIT: a case report focusing on a diagnostic pitfall. \| journal = World J Surg Oncol \| volume = 12 \| issue = \| pages = 186 \| month = \| year = 2014 \| doi = 10.1186/1477-7819-12-186 \| PMID = 24938355 }}</ref>
	*[[IgG4-related systemic disease]].<ref name=pmid21297584/>		*[[IgG4-related systemic disease]].<ref name=pmid21297584/>
			*[[Epithelioid inflammatory myofibroblastic sarcoma]].

	Notes:		Notes:

Michael: tweak

2017-03-08T02:50:25Z

tweak

← Older revision		Revision as of 02:50, 8 March 2017
Line 73:		Line 73:
	==IHC==		==IHC==
	Features - dependent on site:		Features - dependent on site:
	*SMA +ve.<ref name=pmid20350216 >{{Cite journal \| last1 = Shi \| first1 = H. \| last2 = Li \| first2 = Y. \| last3 = Wei \| first3 = L. \| last4 = Sun \| first4 = L. \| title = Primary colorectal inflammatory myofibroblastic tumour: a clinicopathological and immunohistochemical study of seven cases. \| journal = Pathology \| volume = 42 \| issue = 3 \| pages = 235-41 \| month = Apr \| year = 2010 \| doi = 10.3109/00313021003631312 \| PMID = 20350216 }}		*SMA +ve.<ref name=pmid20350216>{{Cite journal \| last1 = Shi \| first1 = H. \| last2 = Li \| first2 = Y. \| last3 = Wei \| first3 = L. \| last4 = Sun \| first4 = L. \| title = Primary colorectal inflammatory myofibroblastic tumour: a clinicopathological and immunohistochemical study of seven cases. \| journal = Pathology \| volume = 42 \| issue = 3 \| pages = 235-41 \| month = Apr \| year = 2010 \| doi = 10.3109/00313021003631312 \| PMID = 20350216 }}</ref>
	</ref>
	*Vimentin +ve.		*Vimentin +ve.
	*ALK-1 +ve.<ref name=pmid15577680>{{Cite journal \| last1 = Tsuzuki \| first1 = T. \| last2 = Magi-Galluzzi \| first2 = C. \| last3 = Epstein \| first3 = JI. \| title = ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. \| journal = Am J Surg Pathol \| volume = 28 \| issue = 12 \| pages = 1609-14 \| month = Dec \| year = 2004 \| doi = \| PMID = 15577680 }}</ref>		*ALK-1 +ve.<ref name=pmid15577680>{{Cite journal \| last1 = Tsuzuki \| first1 = T. \| last2 = Magi-Galluzzi \| first2 = C. \| last3 = Epstein \| first3 = JI. \| title = ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. \| journal = Am J Surg Pathol \| volume = 28 \| issue = 12 \| pages = 1609-14 \| month = Dec \| year = 2004 \| doi = \| PMID = 15577680 }}</ref>

Michael: /* Microscopic */

2014-08-14T18:43:00Z

Microscopic

← Older revision		Revision as of 18:43, 14 August 2014
Line 60:		Line 60:
	*[[Nodular fasciitis]].		*[[Nodular fasciitis]].
	*[[Gastrointestinal stromal tumour]].<ref name=pmid24938355>{{Cite journal \| last1 = Kataoka \| first1 = TR. \| last2 = Yamashita \| first2 = N. \| last3 = Furuhata \| first3 = A. \| last4 = Hirata \| first4 = M. \| last5 = Ishida \| first5 = T. \| last6 = Nakamura \| first6 = I. \| last7 = Hirota \| first7 = S. \| last8 = Haga \| first8 = H. \| last9 = Katsuyama \| first9 = E. \| title = An inflammatory myofibroblastic tumor exhibiting immunoreactivity to KIT: a case report focusing on a diagnostic pitfall. \| journal = World J Surg Oncol \| volume = 12 \| issue = \| pages = 186 \| month = \| year = 2014 \| doi = 10.1186/1477-7819-12-186 \| PMID = 24938355 }}</ref>		*[[Gastrointestinal stromal tumour]].<ref name=pmid24938355>{{Cite journal \| last1 = Kataoka \| first1 = TR. \| last2 = Yamashita \| first2 = N. \| last3 = Furuhata \| first3 = A. \| last4 = Hirata \| first4 = M. \| last5 = Ishida \| first5 = T. \| last6 = Nakamura \| first6 = I. \| last7 = Hirota \| first7 = S. \| last8 = Haga \| first8 = H. \| last9 = Katsuyama \| first9 = E. \| title = An inflammatory myofibroblastic tumor exhibiting immunoreactivity to KIT: a case report focusing on a diagnostic pitfall. \| journal = World J Surg Oncol \| volume = 12 \| issue = \| pages = 186 \| month = \| year = 2014 \| doi = 10.1186/1477-7819-12-186 \| PMID = 24938355 }}</ref>
			*[[IgG4-related systemic disease]].<ref name=pmid21297584/>

	Notes:		Notes:

Michael at 05:26, 13 August 2014

2014-08-13T05:26:05Z

← Older revision		Revision as of 05:26, 13 August 2014
Line 7:		Line 7:
	\| Micro = inflammation ([[plasma cells]] - predominant, lymphocytes, eosinophils), [[spindle cells]] without atypia +/-fascicular architecture, +/-mitoses (none atypical), +/-[[necrosis]], +/-hemorrhage, +/-calcification		\| Micro = inflammation ([[plasma cells]] - predominant, lymphocytes, eosinophils), [[spindle cells]] without atypia +/-fascicular architecture, +/-mitoses (none atypical), +/-[[necrosis]], +/-hemorrhage, +/-calcification
	\| Subtypes =		\| Subtypes =
	\| LMDDx = [[calcifying fibrous pseudotumour]], [[inflammatory fibroid tumour]], [[nodular fasciitis]]		\| LMDDx = [[calcifying fibrous pseudotumour]], [[inflammatory fibroid tumour]], [[nodular fasciitis]], [[gastrointestinal stromal tumour]]
	\| Stains =		\| Stains =
	\| IHC =		\| IHC =

Michael: /* Microscopic */

2014-08-13T05:25:18Z

Microscopic

← Older revision		Revision as of 05:25, 13 August 2014
Line 47:		Line 47:
	**[[Plasma cells]] - predominant - '''key feature'''.<ref name=pmid21297584>{{Cite journal \| last1 = Saab \| first1 = ST. \| last2 = Hornick \| first2 = JL. \| last3 = Fletcher \| first3 = CD. \| last4 = Olson \| first4 = SJ. \| last5 = Coffin \| first5 = CM. \| title = IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link? \| journal = Mod Pathol \| volume = 24 \| issue = 4 \| pages = 606-12 \| month = Apr \| year = 2011 \| doi = 10.1038/modpathol.2010.226 \| PMID = 21297584 }}</ref>		**[[Plasma cells]] - predominant - '''key feature'''.<ref name=pmid21297584>{{Cite journal \| last1 = Saab \| first1 = ST. \| last2 = Hornick \| first2 = JL. \| last3 = Fletcher \| first3 = CD. \| last4 = Olson \| first4 = SJ. \| last5 = Coffin \| first5 = CM. \| title = IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link? \| journal = Mod Pathol \| volume = 24 \| issue = 4 \| pages = 606-12 \| month = Apr \| year = 2011 \| doi = 10.1038/modpathol.2010.226 \| PMID = 21297584 }}</ref>
	**Lymphocytes.		**Lymphocytes.
	**~~Eosinophils~~.		**[[Eosinophil]]s.
	*Spindle cells without atypia.		*Spindle cells without atypia.
	*+/-Fascicular architecture.		*+/-Fascicular architecture.